These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22046617)

  • 41. Sipuleucel-T: When and for Whom to Recommend It.
    Slovin SF
    Oncology (Williston Park); 2017 Dec; 31(12):900-1, 910-2. PubMed ID: 29297175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
    Dawson NA; Roesch EE
    Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comprehensive review of immunotherapies in prostate cancer.
    Maia MC; Hansen AR
    Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sipuleucel-T (Provenge): immunotherapy for metastatic prostate cancer.
    Gaines KK
    Urol Nurs; 2012; 32(2):95-8. PubMed ID: 22690466
    [No Abstract]   [Full Text] [Related]  

  • 45. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.
    Higano CS; Schellhammer PF; Small EJ; Burch PA; Nemunaitis J; Yuh L; Provost N; Frohlich MW
    Cancer; 2009 Aug; 115(16):3670-9. PubMed ID: 19536890
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advanced clinical states in prostate cancer.
    Cheng HH; Lin DW; Yu EY
    Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rationing in urologic oncology: lessons from sipuleucel-T for advanced prostate cancer.
    Peppercorn J; Armstrong A; Zaas DW; George D
    Urol Oncol; 2013 Oct; 31(7):1079-84. PubMed ID: 22305627
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cellular immunotherapy licensed for advanced prostate cancer.
    Traynor K
    Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204
    [No Abstract]   [Full Text] [Related]  

  • 50. Provenge: revolutionary technology or ethical bust?
    Dickerson JB
    Hum Vaccin; 2011 Apr; 7(4):477-80. PubMed ID: 21451262
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer.
    Patel PH; Kockler DR
    Ann Pharmacother; 2008 Jan; 42(1):91-8. PubMed ID: 18094343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sipuleucel-T: in metastatic castration-resistant prostate cancer.
    Plosker GL
    Drugs; 2011 Jan; 71(1):101-8. PubMed ID: 21175243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostate cancer immunotherapy: the path forward.
    Madan RA; Gulley JL
    Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunotherapy: a new option for advanced prostate cancer.
    Harv Mens Health Watch; 2010 Sep; 15(2):1-2. PubMed ID: 20941869
    [No Abstract]   [Full Text] [Related]  

  • 55. Optimizing the efficiency and quality of sipuleucel-T delivery in an academic institution.
    Davis K; Wood S; Dill E; Fesko Y; Bitting RL; Harrison MR; Armstrong AJ; Moul JW; George DJ
    Clin J Oncol Nurs; 2015 Jun; 19(3):297-303. PubMed ID: 26000580
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T.
    McNeel DG; Gardner TA; Higano CS; Kantoff PW; Small EJ; Wener MH; Sims RB; DeVries T; Sheikh NA; Dreicer R
    Cancer Immunol Res; 2014 Oct; 2(10):988-99. PubMed ID: 25189164
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens.
    Kibel AS; Inman BA; Pachynski RK; Vu T; Sheikh NA; Petrylak DP
    J Natl Cancer Inst; 2022 Feb; 114(2):310-313. PubMed ID: 33630063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Not Available].
    Oudard S; Thibault C; Angelergues A; Tartour E; Timsit MO; Mejean A; Michel C; Vano Y
    Bull Cancer; 2016 Nov; 103 Suppl 1():S144-S150. PubMed ID: 28057178
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current role of immunotherapy for the treatment of prostate cancer.
    Porfyris O; Kalomoiris P
    J BUON; 2013; 18(4):809-17. PubMed ID: 24344002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.